Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...

The issuer is solely responsible for the content of this announcement.

The drug is based on a molecule called semaglutide, which mimics the structure of a naturally occurring human hormone called glucagon-like peptide 1 (GLP-1). GLP-1 plays an important role in ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

Relative effects of genetically proxied glucagon‐like peptide‐1 receptor agonism on muscle and fat mass: A Mendelian randomization study. Diabetes, Obesity and Metabolism , 2025; DOI: 10.1111 ...

M&T Bank Corp raised its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 100.0% during the 4th quarter ...

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.

Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...